XRTX Stock Summary and Trading Ideas (Xortx Therapeutics - Common Shares | NASDAQ:XRTX)

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Xortx Therapeutics - Common Shares trades on the NASDAQ stock market under the symbol XRTX.

As of August 21, 2026, XRTX stock price climbed to $2.04 with 1,690 million shares trading.

XRTX has a beta of 0.40, meaning it tends to be less sensitive to market movements. XRTX has a correlation of 0.00 to the broad based SPY ETF.

XRTX has a market cap of $3.71 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, XRTX traded as high as $37.62 and as low as $1.73.

XRTX has underperformed the market in the last year with a price return of -49.0% while the SPY ETF gained +21.7%. XRTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.7% and -4.2%, respectively, while the SPY returned +3.4% and -1.0%, respectively.

XRTX support price is $1.89 and resistance is $2.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XRTX shares will trade within this expected range on the day.